Paul Howe Email & Phone Number

An innovative specialty pharmaceutical company focused on responsible pain management and the development of abuse-deterrent products for multiple specialties.

San Mateo, California, US

• TALPHERA (previously AcelRx Pharmaceuticals, Inc.) is a specialty drug device company focused on developing and commercializing innovative therapies for use in medically supervised settings. Built a commercial team in.
• Successfully sold drug-device to Alora Pharmaceuticals
• Sales Growth of 141% YOY (Q1 2021 vs Q1 2022)
• Achieved 750+ formulary wins and new accounts exceeding the corporate goal of 625 accounts
• Shifted targeting and KPIs to procedural suites vs hospitals to speed up the ordering process
• Pivoted to a new sales model, including, a single decision maker, virtual sales, and programming that generated additional leads that led to all-time quarterly highs in new accounts in 2021

US

• Biopharmaceutical Company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Responsible for building and leading US.
• Exceeded net sales YOY growth increase + 96% 2016 vs 2015, 117% of corporate forecast
• Increased sales from $6 million to $64 million in 2 years, exceeding forecast and coming in below budget. Achievements completed without payer contracts in place.
• Consistently achieve a 90%+ engagement score through culture building and collaboration work streams resulting in extremely high retention rates
• Strategically planned and built a 135 footprint Neuroscience commercial sales infrastructure

Brentford, Middlesex, GB

• Research-based pharmaceutical company developing and promoting medicines in cardiovascular, Respiratory, Neuroscience, Oncology and Vaccines. Role was sales leadership for a 10 state region.
• Grew to the most profitable region in the nation, 32% GTN, ($408 million net revenue) by collaboration with unique state healthcare markets and multiple community leaders, including CEOs of health systems, state.
• Successfully led a team of sales professionals and fourteen direct reports including sales, marketing, and operations to exceed goals and expectations by 124%
• Restructured key roles that had better impact with target health systems leading the region to be the most profitable in the nation.
• Moved the region to a commercial 3rd party focus versus the previous less profitable focused workstreams

• Rapidly growing cardiovascular pharmaceutical company specializing in the development, commercialization, and marketing of prescription cardiovascular therapies (Acquired by GlaxoSmithKline in 2007) Moved into greater.
• As Vice President of Sales, exceeded sales forecasts in both 2006-2007 by 134% and 111%, respectively
• Leadership responsibilities focused on achieving sales forecast through operation and management of sales budget and team of 800 footprint sales team
• Developed engaged culture with highly effective sales strategies, the new start-up reached top tier status in the industry – Verispan Noted that Reliant sales team emerging with a rank of 26 out of Top 60 Pharma.